Spatiotemporal remodeling of the tumor–immune interface during neoadjuvant immunotherapy for oral squamous cell carcinoma: pathological response, resistance, and dynamic biomarkers
- 1Department of Stomatology, Shandong Provincial Hospital Affiliated to Shandong First Medical University
- 2School of Stomatology, Shandong First Medical University & Shandong Academy of Medical Sciences
Abstract
Oral squamous cell carcinoma (OSCC) is locally aggressive and frequently associated with cervical lymph-node metastasis and postoperative recurrence. Recent clinical advances in perioperative immunotherapy have made the neoadjuvant setting an important window for investigating dynamic changes in the tumor–immune microenvironment under therapeutic pressure. However, pathological responses vary substantially among patients, and baseline biomarkers such as the PD-L1 combined positive score (CPS) and tumor mutational burden (TMB) do not reliably identify those most likely to benefit. Evidence from single-cell sequencing, spatial omics, multiplex imaging, and longitudinal liquid-biopsy studies indicates that pathological response is closely associated with antigen presentation, expansion-competent T cells, tertiary lymphoid structures, vascular routes of immune-cell entry, and myeloid–stromal remodeling. In contrast, impaired antigen presentation, T-cell exclusion, immunosuppressive macrophages, cancer-associated fibroblasts, hypoxic metabolism, and lymph-node-specific niches are associated with residual resistance. This review examines spatiotemporal changes at the tumor–immune interface before and after neoadjuvant immunotherapy for OSCC, with an emphasis on pathological response, mechanisms of resistance, and dynamic biomarkers. We also discuss the translational potential of these features for patient stratification and perioperative treatment decision-making.
Related
- Macrophage state in neoadjuvant and perioperative immunotherapy resistance in resectable NSCLC: a critical appraisal of strategies from CSF1R and CD47–SIRPα to CAR-macrophages
- Commentary: Fecal microbiome and metabolome dynamics during immunotherapy-based total neoadjuvant therapy in rectal cancer: associations with treatment response and toxicity
- A pretreatment ECM-high/immune-low transcriptomic score is associated with pathological complete response after neoadjuvant therapy in breast cancer
- Repeated VU0155069 Treatment Is Associated with Region- and Pathological Stage-Specific Dendritic Spine Remodeling in Female 3xTg-AD Mice
- Not all major pathological responses are equal: prognostic heterogeneity and risk stratification after neoadjuvant chemoimmunotherapy in resectable NSCLC.
BibTeX
@article{xue2026spatiotemporal,
title = {{Spatiotemporal remodeling of the tumor–immune interface during neoadjuvant immunotherapy for oral squamous cell carcinoma: pathological response, resistance, and dynamic biomarkers}},
author = {Jingnan Xue and Tingting Jia and Jiaxiang Yu and Shuai Wang and Jin Liang},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.2011622},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.2011622/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Spatiotemporal remodeling of the tumor–immune interface during neoadjuvant immunotherapy for oral squamous cell carcinoma: pathological response, resistance, and dynamic biomarkers
AU - Jingnan Xue
AU - Tingting Jia
AU - Jiaxiang Yu
AU - Shuai Wang
AU - Jin Liang
PY - 2026
DA - 2026/11/02
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.2011622
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.2011622/full
AB - Oral squamous cell carcinoma (OSCC) is locally aggressive and frequently associated with cervical lymph-node metastasis and postoperative recurrence. Recent clinical advances in perioperative immunotherapy have made the neoadjuvant setting an important window for investigating dynamic changes in the tumor–immune microenvironment under therapeutic pressure. However, pathological responses vary substantially among patients, and baseline biomarkers such as the PD-L1 combined positive score (CPS) and tumor mutational burden (TMB) do not reliably identify those most likely to benefit. Evidence from single-cell sequencing, spatial omics, multiplex imaging, and longitudinal liquid-biopsy studies indicates that pathological response is closely associated with antigen presentation, expansion-competent T cells, tertiary lymphoid structures, vascular routes of immune-cell entry, and myeloid–stromal remodeling. In contrast, impaired antigen presentation, T-cell exclusion, immunosuppressive macrophages, cancer-associated fibroblasts, hypoxic metabolism, and lymph-node-specific niches are associated with residual resistance. This review examines spatiotemporal changes at the tumor–immune interface before and after neoadjuvant immunotherapy for OSCC, with an emphasis on pathological response, mechanisms of resistance, and dynamic biomarkers. We also discuss the translational potential of these features for patient stratification and perioperative treatment decision-making.
SN - 1664-3224
ER -